| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/35176972_HAS_TOPIC_C0003253> <https://research.tib.eu/covid-19/entity/35176972_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/35176972_HAS_TOPIC_C0475463> <https://research.tib.eu/covid-19/entity/35176972_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/35176972_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/35176972_HAS_TOPIC_C5387588> <https://research.tib.eu/covid-19/entity/35176972_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'Gobond Testing Technology (Beijing) Co., Ltd., Beijing, People\'s Republic of China.\', \'Department of Science and Development, Beijing Youan Hospital, Capital Medical University, Beijing, People\'s Republic of China.\', \'Yearth Biotechnology Co. Ltd., Changsha, People\'s Republic of China.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Cao_Yu> <https://research.tib.eu/covid-19/entity/Feng_Yingmei> <https://research.tib.eu/covid-19/entity/Feng_Yuchen> <https://research.tib.eu/covid-19/entity/Guo_Lixian> <https://research.tib.eu/covid-19/entity/Li_Peiyao> <https://research.tib.eu/covid-19/entity/Liu_Qiang> <https://research.tib.eu/covid-19/entity/Lu_Li> <https://research.tib.eu/covid-19/entity/Lv_Jing> <https://research.tib.eu/covid-19/entity/Qi_Xiangrong> <https://research.tib.eu/covid-19/entity/Sun_Mingyue> <https://research.tib.eu/covid-19/entity/Wang_Pingping> <https://research.tib.eu/covid-19/entity/Wei_Huihui> <https://research.tib.eu/covid-19/entity/Yang_Jie> <https://research.tib.eu/covid-19/entity/Yu_Xiaoling>
?:doi	10.1080/22221751.2022.2044271
?:doi	<https://research.tib.eu/covid-19/entity/10.1080/22221751.2022.2044271>
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article>
?:journal	Emerging microbes & infections
is ?:pmid of	<https://research.tib.eu/covid-19/entity/35176972>
?:pmid	<https://research.tib.eu/covid-19/entity/35176972>
?:pmid	35176972
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	-1.0
?:rankingScore_hIndex	-1
?:title	Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2022

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/35176972>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/35176972>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all